Lilly
4Q Revenues: $7.4 billion (+22%)
4Q Earnings: $2.1 billion (+42%)
YTD Revenues: $24.5 billion (+10%)
YTD Earnings: $6.2 billion (-26%)
Comments: The company recognized worldwide revenue of $871.2 million in the quarter for bamlanivimab. Excluding bamlanivimab revenue, worldwide revenue grew by 7%. Key growth products launched since 2014, consisting of Trulicity, Verzenio, Taltz, Tyvyt, Olumiant, Jardiance, Emgality, Cyramza, Retevmo, Baqsimi and Basaglarcontributed nearly 12 percentage points of revenue growth and represented approximately 48% of total revenue for the quarter.
 
The U.S. FDA granted Emergency Use Authorization for bamlanivimab for the treatment of mild to moderate COVID-19 in patients at high risk for progressing to severe COVID-19 and/or hospitalization. The U.S. government has committed to purchase a total of 1,450,000 doses of bamlanivimab, which includes 950,000 doses already delivered and an agreement to deliver 500,000 additional doses no later than March 31, 2021.
 
The FDA granted Emergency Use Authorization for baricitinib to be used in combination with remdesivir in hospitalized adult and pediatric with suspected or laboratory confirmed COVID-19 who require supplemental oxygen, invasive mechanical ventilation, or extracorporeal membrane oxygenation (ECMO).